0000000000228503
AUTHOR
S. Pastore
showing 3 related works from this author
Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two
2017
21. Mainzer Allergie-Workshop
2009
Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etan…
2017
The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.